Cilnidipine 10 Metoprolol 50 Tablet
Description
CILROOT-50
Cilnidipine 10 mg and Metoprolol Succinate Extended Release 50 mg Tablets
Division: DIABGLYM
Composition
Each extended-release tablet contains:
Cilnidipine IP — 10 mg
Metoprolol Succinate Extended Release IP equivalent to Metoprolol — 50 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Extended-release oral tablet
Product Description
CILROOT-50 is a scientifically balanced antihypertensive combination of Cilnidipine 10 mg and Metoprolol Succinate Extended Release 50 mg, formulated for the effective management of hypertension and long-term cardiovascular protection. This combination provides dual blood pressure control by combining the advanced dual calcium channel blocking action of Cilnidipine with the sustained beta-1 selective blocking action of Metoprolol Succinate, resulting in superior antihypertensive efficacy, heart rate control, and enhanced cardiovascular and renal protection.
Cilnidipine is a unique dual L-type and N-type calcium channel blocker that reduces peripheral vascular resistance, suppresses sympathetic overactivity, improves renal hemodynamics, and minimizes reflex tachycardia. Metoprolol Succinate Extended Release is a long-acting beta-1 selective blocker that reduces heart rate, myocardial contractility, and cardiac workload while providing sustained 24-hour cardiovascular control.
CILROOT-50 is particularly beneficial in patients with hypertension associated with tachycardia, diabetes, chronic kidney disease, coronary artery disease, metabolic syndrome, obesity, and patients requiring combination antihypertensive therapy with heart rate control.
Technical Knowledge of Cilnidipine and Metoprolol Succinate Extended Release
Cilnidipine blocks both L-type calcium channels in vascular smooth muscle and N-type calcium channels in sympathetic nerve terminals. This dual mechanism reduces arterial vasoconstriction while decreasing sympathetic neurotransmitter release, resulting in sustained blood pressure reduction, improved renal perfusion, reduced glomerular hypertension, and better autonomic control.
Metoprolol Succinate Extended Release selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin secretion. The extended-release formulation provides stable plasma concentrations and sustained therapeutic activity throughout the day.
The combination of Cilnidipine and Metoprolol Succinate Extended Release provides complementary antihypertensive mechanisms with additional cardiovascular, renal, and endothelial protective benefits.
Mechanism of Action
Cilnidipine blocks L-type and N-type calcium channels, relaxes vascular smooth muscle, suppresses sympathetic activity, improves renal blood flow, reduces glomerular pressure, and provides sustained antihypertensive action.
Metoprolol Succinate Extended Release reduces heart rate, decreases myocardial contractility, lowers cardiac output, suppresses renin release, and reduces myocardial oxygen demand through sustained beta-1 receptor blockade.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Dual antihypertensive mechanism
Provides sustained 24-hour blood pressure control
Reduces heart rate and myocardial workload
Supports cardiovascular and renal protection
Improves endothelial function
Reduces sympathetic overactivity
Minimizes reflex tachycardia
Suitable for long-term hypertension management under medical supervision
Clinical Applications
CILROOT-50 is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with coronary artery disease, metabolic syndrome, obesity-associated hypertension, and long-term cardiovascular risk reduction.
Facts About Cilnidipine and Metoprolol Succinate Extended Release
Cilnidipine is an advanced calcium channel blocker with dual L-type and N-type channel blocking properties, providing effective blood pressure control with favorable renal and sympathetic modulation effects. Metoprolol Succinate Extended Release is a long-acting beta-blocker with proven benefits in hypertension, ischemic heart disease, and heart failure. The combination is particularly useful in hypertensive patients requiring both blood pressure reduction and heart rate control.
Key Facts
Dual calcium channel blocker and beta-blocker combination therapy
Cilnidipine 10 mg for vascular and renal protection
Metoprolol Succinate Extended Release 50 mg for sustained heart rate control
Provides sustained 24-hour antihypertensive action
Effective in hypertension with tachycardia and diabetes
Evidence-based cardiovascular combination therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
CILROOT-50 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination.
Why Choose CILROOT-50 for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Cilnidipine 10 mg and Metoprolol Succinate Extended Release 50 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented extended-release formulation
Controlled-release tablet manufacturing technology
Blister and Alu-Alu packaging options
CILROOT-50 from DIABGLYM combines effective blood pressure control, sustained heart rate management, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Cilnidipine and Metoprolol Succinate Extended Release formulation.
